Preamble

The report was updated in 1987 and published as Clinical trials: report of the working party on clinical trials of the Medico-Pharmaceutical Forum (vii + 40 pages).

Aims
The Forum was set up in 1968 to provide a setting for the discussion of problems of interest to both the medical profession and the pharmaceutical industry. At the two yearly statutory meetings such matters were discussed and debated as consultations between the industry and the profession before the withdrawal of medicines from the market by pharmaceutical firms, the obligations of the industry to the profession (and vice-versa) and marketing as seen by the industry. As a result, certain subjects are identified for enquiry in depth; experts are asked to undertake these tasks; and their reports are then analysed and considered by the Forum. Three have now been published: the first on facilities for the early clinical studies of new medicine; the second on academic / industrial relationships; the third as now presented (Preface, page 1).

In 1972, the National Economic Development Office published a report by the Pharmaceutical Working Party of the Chemicals EDC (Focus on Pharmaceuticals, HMSO, 1972), which included comments on clinical trials. The report pointed out that clinical trials in the United Kingdom have a world-wide reputation for quality but that there was room for improvement; in particular poor finishing and confusion on the ethics of payment to investigators. With these and other problems in mind, the NEDO report welcomed the idea of a study by the Medico-Pharmaceutical Forum to evaluate and make recommendations upon the organisation of clinical trials. The Executive committee of the Medico-Pharmaceutical forum considered this suggestion and appointed a working party with the following draft terms of reference:

“To evaluate and make recommendations upon the organisation of clinical trials in the United Kingdom, with particular reference to areas of controversy and misunderstanding and to practical points where errors frequently arise.” (Introduction, page 6).

Contents (31 pages)
Member organisations of the Forum
Preface (John Richardson)
Members of the Working Party on Clinical Trials
Introduction
Report
1. Definitions
2. Controlled trials
3. Uncontrolled trials
4. Clinical trial phases
5. Phase I trials
6. Phase II trials
7. Phase III trials
8. Clinical trial ethics
9. Non-patient volunteer consent
10. Patient consent
11. Trials in patients unable to give valid consent
12. Pre-trial organisation
13. Measurements and assessments
14. Payments
15. Professional indemnity
16. Statistics
17. Patient non-cooperation
18. Combinations
19. “Routine” trials
20. Medical adviser participation in trials
21. Publication
22. Investigator panels
23. Trial wastage
24. Committee on Safety of Medicines
25. Conclusion
Previously published reports by the Forum

Authors
The chairman of the Working Party on Clinical Trials is Dr Brian W Cromie (Hoechst Pharmaceuticals) and the secretary is Dr EAP Croydon (Beecham Pharmaceuticals). The members are Dr A Herxheimer (London Hospital Medical College); Dr D Hughes (Wellcome Foundation and London Hospital); Dr DAW Johnson (Crumpsall Hospital and University of Manchester); Dr C Maxwell (Clinical Research Services Ltd); Dr BNC Prichard (University College Hospital Medical School); Dr JM Simister (WB Pharmaceuticals Ltd); and, Dr GI Watson (Royal College of General Practitioners and Peaslake, Surrey). The author of the preface is Sir John Richardson Bt, MVO, Chairman of the Officers of the forum.